- Pemetrexed is a multitarget anticancer antifolate agent that exerts its action by disrupting crucial folate-dependent metabolic processes essential for cell replication.
Pemetrexed is for Intravenous Infusion only
Combination Use With Cisplatin:
The recommended dose of pemetrexed is 500 mg/m2 administered as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle. The recommended dose of cisplatin is 75 mg/m2 infused over 2 hours beginning approximately 30 minutes after the end of pemetrexed administration. Patients should receive hydration consistent with local practice prior to and / or after receiving cisplatin. (for details see cisplatin pack insert)
Single-Agent Use:
The recommended dose of Pemetrexed is 500 mg/m2 administered as an intravenous infusion over 10minutes on Day 1 of each 21-day cycle.